Seema Singhal

View Scopus Profile

Phone+1 312 695 8697
Emails-singhal@northwestern.edu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Research Interests

Myeloma, Transplantation

Certifications and Licenses

Internal Medicine

Training Experience

1991	Residency, Bombay University, India
1992	Fellowship, Hadassah University Hospital, Israel

Education/Academic qualification

MD, University of Mumbai

… → 1991

Research interests

Amyloidosis
Monoclonal Antibodies
Multiple Myeloma
Plasma Cell Disorders
Stem Cell Transplant
Waldenstroms

Fingerprint

Dive into the research topics where Seema Singhal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

10 Active
42 Finished

Prot #BB2121-MM-007: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)
Singhal, S.
DrugDev Inc., Celgene Corporation
8/6/21 → 8/6/24
Project: Research project
Prot #C1071003: MAGNETISMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and On
Singhal, S.
Pfizer Inc.
7/21/21 → 7/21/24
Project: Research project
Prot #209627: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
Singhal, S.
Quintiles, Inc., GlaxoSmithKline LLC
3/12/21 → 3/12/24
Project: Research project
Prot #209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Singhal, S.
Quintiles, Inc., GlaxoSmithKline LLC
3/10/21 → 3/10/24
Project: Research project
Prot #BB2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming for Commercial Release
Singhal, S.
DrugDev Inc., Celgene Corporation
12/8/20 → 12/8/23
Project: Research project

16022 Citations
175 Article
23 Review article
21 Letter
10 Comment/debate
More

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., Singhal, S., Pawlish, K., Peters, E. S., Bock, C., Mohrbacher, A., Stram, A., Berndt, S. I., Blot, W. J., Casey, G., Stevens, V. L. & 50 others, Kittles, R., Goodman, P. J., Diver, W. R., Hennis, A., Nemesure, B., Klein, E. A., Rybicki, B. A., Stanford, J. L., Witte, J. S., Signorello, L., John, E. M., Bernstein, L., Stroup, A. M., Stephens, O. W., Zangari, M., Van Rhee, F., Olshan, A., Zheng, W., Hu, J. J., Ziegler, R., Nyante, S. J., Ingles, S. A., Press, M. F., Carpten, J. D., Chanock, S. J., Mehta, J., Colditz, G. A., Wolf, J., Martin, T. G., Tomasson, M., Fiala, M. A., Terebelo, H., Janakiraman, N., Kolonel, L., Anderson, K. C., Le Marchand, L., Auclair, D., Chiu, B. C. H., Ziv, E., Stram, D., Vij, R., Bernal-Mizrachi, L., Morgan, G. J., Zonder, J. A., Huff, C. A., Lonial, S., Orlowski, R. Z., Conti, D. V., Haiman, C. A. & Cozen, W., Jan 14 2020, In: Blood Advances. 4, 1, p. 181-190 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States
Yu, Y., Wade, N. B., Hwang, A. E., Nooka, A. K., Fiala, M. A., Mohrbacher, A., Peters, E. S., Pawlish, K., Bock, C., van Den, D. J., Rand, K. A., Stram, D., Conti, D. V., Auclair, D., Colditz, G. A., Mehta, J., Haiman, C. A., Terebelo, H., Janakiraman, N., Singhal, S. & 9 others, Chiu, B., Vij, R., Bernal-Mizrachi, L., Zonder, J. A., Huff, C. A., Lonial, S., Orlowski, R. Z., Cozen, W. & Ailawadhi, S., Oct 1 2020, In: JCO Oncology Practice. 16, 10, p. E1169-E1180
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines
Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E. & 11 others, Martin, T., Omel, J., Raje, N., Sborov, D., Singhal, S., Stockerl-Goldstein, K., Tan, C., Weber, D., Johnson-Chilla, A., Keller, J. & Kumar, R., 2019, In: JNCCN Journal of the National Comprehensive Cancer Network. 17, 10, p. 1154-1165 12 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
43 Scopus citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
KEYNOTE-183 Investigators, Sep 2019, In: The Lancet Haematology. 6, 9, p. e459-e469
Research output: Contribution to journal › Article › peer-review
82 Scopus citations
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan-Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In: Blood cancer journal. 9, 2, 17.
Research output: Contribution to journal › Article › peer-review
16 Scopus citations

Seema Singhal

Personal profile

Research Interests

Certifications and Licenses

Training Experience

Education/Academic qualification

Research interests

Fingerprint

Network

Dive into details

Prot #BB2121-MM-007: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Prot #C1071003: MAGNETISMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and On

Prot #209627: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

Prot #209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

Prot #BB2121-EAP-001: Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming for Commercial Release

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States

Multiple myeloma, version 1.2020 featured updates to the NCCN guidelines

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Seema Singhal

Personal profile

Research Interests

Certifications and Licenses

Training Experience

Education/Academic qualification

Research interests

Fingerprint

Network

Grants

Research Output